IBDEI0J3 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8962,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,8963,0)
 ;;=250.10^^38^505^10
 ;;^UTILITY(U,$J,358.3,8963,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8963,1,4,0)
 ;;=4^DMII w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,8963,1,5,0)
 ;;=5^250.10
 ;;^UTILITY(U,$J,358.3,8963,2)
 ;;=^331783
 ;;^UTILITY(U,$J,358.3,8964,0)
 ;;=250.20^^38^505^9
 ;;^UTILITY(U,$J,358.3,8964,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8964,1,4,0)
 ;;=4^DMII w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,8964,1,5,0)
 ;;=5^250.20
 ;;^UTILITY(U,$J,358.3,8964,2)
 ;;=^331787
 ;;^UTILITY(U,$J,358.3,8965,0)
 ;;=250.40^^38^505^12
 ;;^UTILITY(U,$J,358.3,8965,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8965,1,4,0)
 ;;=4^DMII w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,8965,1,5,0)
 ;;=5^250.40
 ;;^UTILITY(U,$J,358.3,8965,2)
 ;;=^331795
 ;;^UTILITY(U,$J,358.3,8966,0)
 ;;=250.50^^38^505^8
 ;;^UTILITY(U,$J,358.3,8966,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8966,1,4,0)
 ;;=4^DMII w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,8966,1,5,0)
 ;;=5^250.50
 ;;^UTILITY(U,$J,358.3,8966,2)
 ;;=^331799
 ;;^UTILITY(U,$J,358.3,8967,0)
 ;;=250.60^^38^505^11
 ;;^UTILITY(U,$J,358.3,8967,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8967,1,4,0)
 ;;=4^DMII w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,8967,1,5,0)
 ;;=5^250.60
 ;;^UTILITY(U,$J,358.3,8967,2)
 ;;=^331803
 ;;^UTILITY(U,$J,358.3,8968,0)
 ;;=250.70^^38^505^13
 ;;^UTILITY(U,$J,358.3,8968,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8968,1,4,0)
 ;;=4^DMII w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,8968,1,5,0)
 ;;=5^250.70
 ;;^UTILITY(U,$J,358.3,8968,2)
 ;;=^331807
 ;;^UTILITY(U,$J,358.3,8969,0)
 ;;=251.0^^38^505^16
 ;;^UTILITY(U,$J,358.3,8969,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8969,1,4,0)
 ;;=4^HYPOGLYCEMIC COMA
 ;;^UTILITY(U,$J,358.3,8969,1,5,0)
 ;;=5^251.0
 ;;^UTILITY(U,$J,358.3,8969,2)
 ;;=^60589
 ;;^UTILITY(U,$J,358.3,8970,0)
 ;;=272.0^^38^506^4
 ;;^UTILITY(U,$J,358.3,8970,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8970,1,4,0)
 ;;=4^PURE HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,8970,1,5,0)
 ;;=5^272.0
 ;;^UTILITY(U,$J,358.3,8970,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,8971,0)
 ;;=272.1^^38^506^5
 ;;^UTILITY(U,$J,358.3,8971,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8971,1,4,0)
 ;;=4^PURE HYPERGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,8971,1,5,0)
 ;;=5^272.1
 ;;^UTILITY(U,$J,358.3,8971,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,8972,0)
 ;;=272.2^^38^506^3
 ;;^UTILITY(U,$J,358.3,8972,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8972,1,4,0)
 ;;=4^MIXED HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,8972,1,5,0)
 ;;=5^272.2
 ;;^UTILITY(U,$J,358.3,8972,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,8973,0)
 ;;=272.4^^38^506^1
 ;;^UTILITY(U,$J,358.3,8973,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8973,1,4,0)
 ;;=4^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,8973,1,5,0)
 ;;=5^272.4
 ;;^UTILITY(U,$J,358.3,8973,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,8974,0)
 ;;=272.6^^38^506^2
 ;;^UTILITY(U,$J,358.3,8974,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8974,1,4,0)
 ;;=4^LIPODYSTROPHY
 ;;^UTILITY(U,$J,358.3,8974,1,5,0)
 ;;=5^272.6
 ;;^UTILITY(U,$J,358.3,8974,2)
 ;;=^71106
 ;;^UTILITY(U,$J,358.3,8975,0)
 ;;=253.0^^38^507^1
 ;;^UTILITY(U,$J,358.3,8975,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8975,1,4,0)
 ;;=4^ACROMEGALY AND GIGANTISM
 ;;^UTILITY(U,$J,358.3,8975,1,5,0)
 ;;=5^253.0
 ;;^UTILITY(U,$J,358.3,8975,2)
 ;;=^2351
 ;;^UTILITY(U,$J,358.3,8976,0)
 ;;=255.0^^38^507^2
 ;;^UTILITY(U,$J,358.3,8976,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8976,1,4,0)
 ;;=4^CUSHING'S SYNDROME
 ;;^UTILITY(U,$J,358.3,8976,1,5,0)
 ;;=5^255.0
 ;;^UTILITY(U,$J,358.3,8976,2)
 ;;=^29802
 ;;
 ;;$END ROU IBDEI0J3
